Screener
Sana Biotechnology SANA Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Sana Biotechnology’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216769
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| General and administrative | 11,462 | 11,484 |
| Total operating expenses | 48,614 | 50,630 |
| Loss from operations | (48,614) | (50,630) |
| Interest income, net | 951 | 992 |
| Other income, net | 453 | 249 |
| Net loss | $(47,210) | $(49,389) |
| Net loss per common share – basic and diluted | $(0.17) | $(0.21) |
| Weighted-average number of common shares – basic and diluted | 276,856 | 237,578 |
Item 1. Financial Statements
FAQ
- What is Sana Biotechnology's net income?
- Sana Biotechnology (SANA) reported net income of -$47.21M in Q1 2026.
- How has Sana Biotechnology's net income changed year-over-year?
- Sana Biotechnology's net income increased by 4.4% year-over-year, from -$49.39M to -$47.21M.
- What is the long-term trend for Sana Biotechnology's net income?
- Over 4 years (2021 to 2025), Sana Biotechnology's net income has grown at a -9.0% compound annual growth rate (CAGR), from -$355.93M to -$244.17M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Sana Biotechnology's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude